Compounded semaglutide currently occupies a legally precarious position. As of April 2025, semaglutide is no longer on the FDA’s drug shortage list, which removes the primary legal pathway that allowed large-scale compounding pharmacies to produce it. Smaller, traditional compounding pharmacies face a different but equally challenging restriction: they cannot routinely compound drugs that are “essentially copies” of commercially available products. The short answer is that most compounded semaglutide being sold today lacks a clear legal basis under federal law.
Why the Shortage List Matters
Federal law carves out two pathways for legal drug compounding, known as Section 503A and Section 503B of the Food, Drug, and Cosmetic Act. Section 503B covers outsourcing facilities, which are larger operations that can produce compounded drugs without individual prescriptions in hand. These facilities were only permitted to compound semaglutide because it appeared on the FDA’s official drug shortage list. That listing has been removed. Semaglutide no longer appears on the 503B bulks list or the FDA’s drug shortage list, meaning outsourcing facilities have no current legal basis to compound it.
Section 503A covers traditional compounding pharmacies, the kind your local pharmacist might operate. These pharmacies can compound medications for individual patients based on valid prescriptions, but there’s a critical limitation: they cannot regularly compound drugs that are essentially copies of commercially available products. The FDA considers a compounded drug an “essentially a copy” if it has the same active ingredient in the same or similar strength and can be used by the same route of administration as the brand-name version. Since Ozempic and Wegovy are commercially available injectable semaglutide products, a 503A pharmacy compounding injectable semaglutide in similar doses runs directly into this restriction.
The Salt Form Problem
Some compounding pharmacies have tried to work around these restrictions by using salt forms of semaglutide, specifically semaglutide sodium or semaglutide acetate, rather than the base form used in Ozempic and Wegovy. The FDA has pushed back hard on this practice. The agency has stated plainly that these salt forms are “different active ingredients” from what’s in the approved drugs and that it is “not aware of any lawful basis for their use in compounding.”
Beyond the legal question, there’s a safety concern. The FDA has said it does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in approved semaglutide products. In other words, even if you receive a compounded product labeled “semaglutide,” the actual substance may behave differently in your body if it’s made from a salt form.
Novo Nordisk’s Legal Campaign
The manufacturer of Ozempic and Wegovy, Novo Nordisk, has aggressively pursued legal action against compounders. The company has filed 132 lawsuits in federal courts across 40 states, resulting in 44 permanent injunctions that prohibit defendants from compounding semaglutide and from falsely claiming their products are FDA-approved, safe, or equivalent to Novo Nordisk’s branded medications. Courts have also ordered some defendants to forfeit profits.
The lawsuits target not just pharmacies but also telehealth companies that Novo Nordisk alleges are steering patients toward compounded semaglutide under what the company calls a “fake guise of personalization.” The legal argument is that these operations violate state corporate practice of medicine laws by having corporations, rather than independent physicians, drive prescribing decisions. Whether or not you agree with Novo Nordisk’s motives, the string of successful injunctions signals that courts are broadly siding with the manufacturer’s legal position.
What a Legitimate Compounding Pharmacy Looks Like
Even during the shortage period, legal compounding required specific conditions. A 503A pharmacy must compound based on a valid prescription written for a specific, identified patient by a licensed prescriber. The prescription cannot be vague or written in bulk. The pharmacist must have an established relationship with the patient or the prescribing provider. And the pharmacy must follow sterile compounding standards, since injectable medications carry serious risks of contamination, incorrect dosing, or infection if prepared improperly.
If you’re evaluating an online source, look for these warning signs of an unsafe operation: no requirement for a valid prescription, discounts that seem too good to be true, acceptance of only cryptocurrency or peer-to-peer payment, and no licensed pharmacist available for questions. The National Association of Boards of Pharmacy accredits legitimate online pharmacies, and websites ending in “.pharmacy” have been verified. Unlike a logo, that domain extension cannot be faked.
Where Things Stand Now
With the shortage resolved, the legal ground beneath compounded semaglutide has largely collapsed. Outsourcing facilities under 503B have lost their shortage-based authorization entirely. Traditional pharmacies under 503A face the “essentially a copy” restriction, which the FDA has signaled it intends to enforce. Salt forms of semaglutide have no recognized legal basis. And Novo Nordisk continues winning court orders against compounders and their telehealth partners.
Some compounders may continue to operate in the gap between FDA guidance and active enforcement, but purchasing from them carries both legal and health risks. Compounded injectables made outside proper oversight may have incorrect potency, contamination, or unknown pharmacological properties. The FDA has been explicit that compounded semaglutide products are not FDA-approved and should not be represented as safe or equivalent to Wegovy or Ozempic.
The Patent Timeline
Novo Nordisk’s U.S. patent on semaglutide is set to expire in 2032. Until then, generic versions cannot legally enter the American market. The picture looks different internationally: China’s patent expires in 2026, and several major pharmaceutical companies are planning generic launches between 2025 and 2027 for non-U.S. markets. For American consumers, though, the realistic timeline for cheaper, FDA-approved alternatives is still years away.